Advertisement

Topics

Foamix Announces Additional Positive Topline Results from Third Phase 3 Trial Evaluating FMX101

12:43 EDT 1 Oct 2018 | Investing News Network

Foamix Pharmaceuticals (NASDAQ:FOMX) a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced additional topline results from its third Phase 3 clinical trial (FX2017-22) of FMX101 for the treatment of moderate-to-severe acne. As quoted in the press release: As the company previously communicated, … Continued

The post Foamix Announces Additional Positive Topline Results from Third Phase 3 Trial Evaluating FMX101 appeared first on Investing News Network.

Original Article: Foamix Announces Additional Positive Topline Results from Third Phase 3 Trial Evaluating FMX101

NEXT ARTICLE

More From BioPortfolio on "Foamix Announces Additional Positive Topline Results from Third Phase 3 Trial Evaluating FMX101"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Acne
Acne is a common skin condition that causes spots to develop on the skin, usually on the face, back and chest..  The spots can range from blackheads and whiteheads which are often mild, to inflamed pus-filled pustules and cysts, which can be severe ...